Australian Institute of Health and Welfare (2022) Diabetes: Australian facts, AIHW, Australian Government, accessed 07 December 2022.
Australian Institute of Health and Welfare. (2022). Diabetes: Australian facts. Retrieved from https://www.aihw.gov.au/reports/diabetes/diabetes
Diabetes: Australian facts. Australian Institute of Health and Welfare, 13 July 2022, https://www.aihw.gov.au/reports/diabetes/diabetes
Australian Institute of Health and Welfare. Diabetes: Australian facts [Internet]. Canberra: Australian Institute of Health and Welfare, 2022 [cited 2022 Dec. 7]. Available from: https://www.aihw.gov.au/reports/diabetes/diabetes
Australian Institute of Health and Welfare (AIHW) 2022, Diabetes: Australian facts, viewed 7 December 2022, https://www.aihw.gov.au/reports/diabetes/diabetes
Get citations as an Endnote file:
PDF | 12.5Mb
The COVID-19 pandemic has affected Australia’s population and health-care system in many ways, including: economic expenditure, mortality, disability, the health workforce and disease surveillance.
Diabetes is one of many conditions correlated with greater health consequences throughout the COVID-19 pandemic including increased risk of complication and mortality (Peric and Stulnig 2020). This section explores the impact of COVID-19 in Australia on diabetes risk factors, new onset diabetes and people living with diabetes.
Data available to assess the impact of COVID on diabetes are still evolving across the continuing pandemic period and are limited by the availability of data covering the relevant time period.
Maintaining a healthy lifestyle, including healthy dietary patterns and being physically active, is important for reducing type 2 diabetes risk and improving outcomes for people living with diabetes. No diabetes-specific data are available for changes in behavioural risk factors across the COVID-19 pandemic. However, the Australian Bureau of Statistics (ABS) Household Impacts of COVID-19 Survey is a longitudinal survey of around 1,000 people aged 18 and over in private dwellings that provides regular data on changes in health behaviours.
According to the ABS Household Impacts of COVID-19 Survey, in April 2020:
Of those adults who usually drank alcohol:
Of those who usually smoked (cigarettes, cigars, e-cigarettes or other tobacco products):
Some studies have proposed a link between COVID-19, hyperglycaemia and new onset diabetes (Sathish et al 2021). In the 12-month periods to March 2021 and March 2022, the National Diabetes Services Scheme (NDSS) had 118,000 and 119,000 new registrants, respectively. Registrations were higher in both periods than any previous 12 months recorded. These new registrations were an increase of 17% compared with the 12 months recorded to March 2020. The largest increase in registration was found among people with gestational diabetes (Diabetes Australia 2022).
However, these new registrations may be, at least in part, people who were previously diagnosed with diabetes and only registering with the NDSS during the pandemic. The increase in registrations also may be influenced by changes to the NDSS to simplify the usual processes to register (Andrikopoulos and Johnson 2020). Further monitoring is required to assess increases in diabetes diagnosis during the COVID-19 pandemic.
ABS provisional mortality data (which includes only deaths certified by general practitioners (GPs) show that from January to December 2020, the age-standardised death rates suggest that the COVID-19 pandemic in Australia did not lead to an increase in mortality for diabetes (AIHW 2021a). Age-standardised death rates were similar for diabetes in 2020 and between 2015 and 2019.
According to the ABS COVID-19 Mortality data from January 2020 to March 2022, pre-existing chronic conditions such as diabetes were reported on death certificates for 3,600 (73%) of the 4,900 deaths due to COVID-19 (ABS 2022). Diabetes was a pre-existing condition in 20% of the 3,600 deaths.
In 2020–21, there were over 4,700 hospitalisations in Australia that involved a COVID-19 diagnosis. Around 42% of hospitalisations with a diagnosis of COVID-19 had one or more diagnosed comorbid conditions, such as type 2 diabetes or cardiovascular disease, an increase from 25% in 2019–20. Of the 4,700 hospitalisations involving a COVID-19 diagnosis, the most common comorbid conditions associated with COVID-19 hospitalisations over this period were type 2 diabetes (20%) and cardiovascular disease (which includes coronary heart disease and a range of other heart, stroke and vascular diseases) (20%) (AIHW 2022).
Of those with a recorded comorbid diagnosis of type 2 diabetes:
These results may be impacted by people with type 2 diabetes being more likely to be older and therefore more likely to have severe COVID-19.
People living with diabetes require regular contact with GPs, endocrinologists and allied health services including dietitians and podiatrists to optimise glucose control and reduce risk of diabetes complications. To limit the spread of COVID-19, restrictions were put in place to contain its impact in the community. By the end of March 2020, non-essential businesses and activities had shut down, with people urged to stay at home. As part of these restrictions, many health services were suspended or required to operate in new or different ways. While this may have limited people’s access to and use of these services, in some cases, new or additional services were made available through changes to health service delivery models, policies and programs (AIHW 2021b).
The initial temporary changes to telehealth items in the Medicare Benefits Schedule (MBS) and bulk billing criteria have bridged these issues, but these services were less suitable for complex care which often require face-to-face consultations. The scope of telehealth services was refined over time to make them more suitable for complex care, however, the scope of telephone services has been reduced since July 2021 to focus on more straightforward services.
People avoiding and/or delaying medical care for diabetes during the COVID-19 pandemic has been an emerging global issue. Research has already shown a significant increase in the frequency of severe diabetic ketoacidosis at presentation of type 1 diabetes during the initial period of COVID-19 restrictions in Australia (Lawrence et al. 2021). Presentations with severe ketoacidosis increased from 5% in the pre-COVID-19 period to 45% during May–March 2020.
MedicineInsight is a longitudinal general practice dataset managed by NPS MedicineWise which was established in 2011. NPS MedicineWise undertook a study looking at the 6 months of March to August 2020 (COVID period) compared with the 6 months of March to August 2019 (pre-COVID period) to assess changes to general practice attendance.
Over the 6-month COVID period, the mean number of clinical encounters per patient among patients without a record of diabetes increased when compared with the pre-COVID period. However, there was no significant change in the mean number of clinical encounters per patient among patients with a record of type 2 diabetes when comparing the 6-month pandemic period to the corresponding 6-month period in 2019. The monthly rate of encounters where the patient had a record of type 2 diabetes fell to 59.6 per 1000 encounters in April 2020 before increasing to approximately 80 per 1000 encounters in subsequent months (Figure 1) (NPS MedicineWise 2020).
The chart shows the monthly mean clinical encounters among patients with a record of type 2 diabetes during the COVID and pre-COVID periods. The monthly rate of encounters where the patient had a record of type 2 diabetes fell from 79 to 60 per 1000 encounters in April 2020 before increasing to approximately 80 per 1000 encounters by June 2020, above the levels recorded in the equivalent pre-COVID period in 2019.
According to the National Hospitals Morbidity Database (NHMD), hospital separations fell in March–April 2020 for both principal and additional diagnosis of diabetes, which may be associated with the effects of the pandemic’s first wave (Figure 2). Similar results were found across type 1, type 2 and other diabetes.
The chart shows the number of diabetes hospitalisations by diagnosis type and month between 2015–16 and 2019–20. Hospital separations fell in March–April 2020 for both principal and additional diagnosis of diabetes, with a more notable drop in hospitalisations with an additional diagnosis of diabetes.
In 2019–20, the average number of monthly diabetes-related ED presentations was 1,500. The rate of monthly diabetes-related ED presentations:
The chart shows emergency department (ED) presentations per 100,000 population by month between July 2018 and June 2021. The rate of monthly diabetes-related ED presentations ranged between 4.7 and 6.6. presentations per 100,000 population between July 2019 and June 2020. This rate was lowest in April 2020 (4.7 per 100,000 population) and highest in June 2020 (6.6 per 100,000 population).
No data are available on the use of allied health services for people living with diabetes, but total attendance for the Australian population are available. According to the Medicare Benefits Scheme:
According to NPS MedicineWise analysis of MedicineInsight, the rate of HbA1c tests over the 6-months from 1 March 2020 to 31 August 2020 was not significantly different from the pre-COVID period, when looking at all regularly attending patients. However, the rate of HbA1c testing did fall significantly among regularly attending patients with a record of type 2 diabetes despite the rate of type 2 diabetes encounters remaining similar in both time periods. In the pre-COVID period, the average monthly rate of HbA1c testing among patients with a record of type 2 diabetes was 126.1 per 1000 clinical encounters, which fell to 109.0 tests per 1,000 clinical encounters in the COVID period (Table 1).
In April 2020, there was a significant decline in the rate of HbA1c tests performed. The rate of tests for all patients fell from 32 tests per 1,000 clinical encounters in April 2019 to 21 tests per 1,000 clinical encounters. The rate of testing for patients with a record of type 2 diabetes fell from 120 tests per 1,000 clinical encounters in April 2019 to 77 tests per 1,000 clinical encounters in April 2020 (NPS MedicineWise 2020).
1 March–31 Aug 2019
1 March–31 Aug 2020
*Reported as the mean (per 1000 encounters) (95% CI); or median (quartiles)
Source: NPS MedicineWise (2020).
Imai et al. (2020) undertook a study of the impact of COVID-19 on HbA1c monitoring using data from over 800 general practices (456 from Victoria and 347 from New South Wales) from January 2018 to December 2020. The volume of HbA1c monitoring in 2020 during the weeks of the first wave of COVID-19 (approximately March-May) decreased by 19.1% in New South Wales and 25.6% in Victoria, compared to the average volume of 2018–2019. Although it was not as large as the first wave, there was another fall in the total HbA1c testing volume in 2020 during the weeks of the second wave (approximately June–September).
The study also examined the number of patients living with type 2 diabetes who had records of HbA1c testing in both 2018 and 2019 (n=22,804 in Victoria, n = 15,399 in New South Wales) and their HbA1c testing frequencies. Approximately 14%–15% of these patients did not have HbA1c testing in 2020 (15.3% in Victoria, 14.1% in New South Wales). The number of patients who had multiple HbA1c tests also decreased in 2020 in both states (Figure 4).
Source: Imai et al. 2020.
In 2020, the Australasian Diabetes in Pregnancy Society, the Australian Diabetes Society, the Australian Diabetes Educators Association and Diabetes Australia, jointly provided temporarily revised guidelines for gestational diabetes screening in response to the COVID-19 pandemic. The guidelines aim to reduce both the number of women attending and the amount of time spent at pathology collection centres during times of elevated contagion risk.
The COVID-19 guidelines replace the oral glucose tolerance test (OGTT) with HbA1c testing in the first trimester and Fasting Blood Glucose (FBG) between 24 and 28 weeks for those not diagnosed with gestational diabetes from the initial HbA1c result. For those with a resulting FBG of 4.7–5.0 mmol/L, an OGTT is recommended while an FBG ≥5.1mmol/L is diagnostic of gestational diabetes (Diabetes Australia 2020).
These guidelines (and other COVID-related factors) likely influenced a sharp decline in the number of women receiving an OGTT or oral glucose challenge test (OGCT) for the screening of gestational diabetes throughout April to June 2020 with an overall 11% drop in the annual numbers between 2019 and 2020 (from 184,000 to 163,000, respectively) (Figure 5). This drop coincided with a 25% increase in HbA1c testing for the management of pre-existing diabetes where the patient is pregnant and a 2% increase in claims for HbA1c testing for the diagnosis of diabetes – both MBS items likely used as a substitute for the use of the OGTT for the detection of gestational diabetes during COVID.
Recent retrospective studies have suggested the temporarily revised guidelines could lead to an under detection of gestational diabetes of between 25%–29% (van Gemert et al. 2020; Zhu et al. 2021). With the National Hospitals Morbidity Database (NHMD) being the primary data source to report gestational diabetes incidence in AIHW monitoring reports, the impact on the incidence of gestational diabetes using NHMD data won’t be evident until late 2022 with the release of the 2021–22 NHMD. While MBS data processed to 1 August 2021 indicates the number of women receiving the OGTT and OGCT had returned to pre-COVID levels, further monitoring will determine the impact of successive waves of the COVID-19 pandemic on gestational diabetes screening and subsequent incidence numbers.
The chart shows the number women who received MBS-subsidised services for the diagnosis of gestational diabetes and management of pre-existing diabetes in pregnancy, by month, April 2019 to August 2021. There was a sharp decline in the number of women receiving the oral glucose tolerance test for the screening of gestational diabetes throughout April to June 2020 with an overall 11% drop in the annual numbers between 2019 and 2020 (from 184,000 to 163,000, respectively). By January 2021, the numbers had returned to pre-COVID levels.
The COVID-19 pandemic has affected both patients and health practitioners in terms of the number of medical services, type of services and the way in which services are delivered (Sutherland et al. 2020). Medication access and supply has also been affected.
Analysis of the total volume of Pharmaceutical Benefits Scheme (PBS) prescriptions dispensed for ATC group A10, Drugs used in diabetes dispensed during 2019–20 and 2020–21 shows little change from 2018–19 when accounting for the expected increase in prescriptions dispensed over time. During 2019–20 and 2020–21, 15.4 and 16.5 million scripts for group A10 were dispensed, compared with 14.3 million for 2018–19 (Figure 6), a 7.8% increase from 2018–19 to 2019–20, and a 7.6% increase from 2019–20 to 2020–21.
The chart shows the number of prescriptions dispensed for diabetes medicines by quarter between 2017–18 and 2020–21. During 2019–20 and 2020–21, 16.5 and 15.4 million scripts for group A10 were dispensed, compared with 14.3 million for 2018–19, a 7.8% increase from 2018–19 to 2019–20, and a 7.6% increase from 2019–20 to 2020–21.
There were, however, changes in consumer behaviour. An unusually high volume of diabetes scripts was dispensed in March 2020 (1.6 million), coinciding with the introduction of national restrictions, followed by a decrease in April 2020 (1.2 million) (Figure 7).
In March 2020, the Australian Government implemented temporary changes to medicines regulation to support Australians’ continued access to PBS medicines during the COVID-19 pandemic. Some of these changes were in response to the dramatic increase in demand for medicines during early March, which resulted in pharmacies and wholesalers reporting medicine shortages.
The measures included a restriction on the quantity of medicines purchased to discourage unnecessary medicine stockpiling, continued dispensing emergency measures to allow one month supply of a patient’s usual medicines without a prescription, a home delivery service for eligible patients, digital image-based prescriptions to support telehealth medical services, and arrangements for medicine substitution by pharmacists without prior approval from the prescribing doctor (AIHW 2020).
The chart shows the number of prescriptions dispensed for diabetes medicines by month between 2017–18 and 2020–2021. An unusually high volume of diabetes scripts was dispensed in March 2020 (1.6 million), coinciding with the introduction of national restrictions, followed by a decrease in April 2020 (1.2 million).
ABS (Australian Bureau of Statistics) (2022) COVID-19 Mortality in Australia: Deaths registered until 31 March 2022, ABS, Australian Government, accessed 9 March 2022.
Australian Institute of Health and Welfare (AIHW) (2020) Impacts of COVID-19 on Medicare Benefits Scheme and Pharmaceutical Benefits Scheme service use, AIHW, Australian Government, accessed 01 June 2022.
AIHW (2021a) The first year of COVID-19 in Australia: direct and indirect health effects, AIHW, Australian Government, accessed 1 December, 2021.
AIHW (2021b) Impacts of COVID-19 on Medicare Benefits Scheme and Pharmaceutical Benefits Scheme: quarterly data, AIHW Australian Government, accessed 15 November 2021.
AIHW (2022) Admitted patients, AIHW, Australian Government, accessed 3 June 2022.
Andrikopoulos S and Johnson G (2020) The Australian response to the COVID-19 pandemic and diabetes – Lessons learned’, Diabetes research and clinical practice, 165:108246, doi: 10.1016/j.diabres.2020.108246
Diabetes Australia (2020) Diagnostic Testing for Gestational diabetes mellitus (GDM) during the COVID 19 pandemic: Antenatal and postnatal testing advice, Diabetes Australia, accessed 1 December 2021.
Diabetes Australia (2022) Diabetes data snapshots (March 2021 and March 2022), National Diabetes Services Scheme website, accessed 3 May 2022.
Imai C, Hardie RA, Thomas J, Wabe N and Georgiou A (2020) The impact of the COVID-19 pandemic on general practice-based HbA1c monitoring in type 2 diabetes, Macquarie University website, accessed 15 November, 2021.
Lawrence C, Seckold R, Smart C, King BR, Howley P, Feltrin R, Smith TA, Roy R and Lopez P (2021) Increased paediatric presentations of severe diabetic ketoacidosis in an Australian tertiary Centre during the COVID‐19 pandemic, Diabetic Medicine, 38(1):e14417, doi: 10.1111/dme.14417.
NPS MedicineWise (2020) MedicineInsight report: HbA1c testing in MedicineInsight patients newly diagnosed, or with a history of diabetes in 2018–2019, Sydney, NPS MedicineWise.
Peric S and Stulnig TM (2020) Diabetes and COVID-19, Wiener Klinische Wochenschrift, 132(13):356–61.
Sathish T, Kapoor N, Cao Y, Tapp RJ and Zimmet P (2021) Proportion of newly diagnosed diabetes in COVID-19 patients: A systematic review and meta-analysis, Diabetes Obesity Metabolism. 1;23(3):870-4, doi: 10.1111/dom.14269.
Sutherland et al. (2020) Impact of COVID-19 on healthcare activity in NSW, Australia, Public health Research and Practice, 30(4).
Van Gemert TE, Moses RG, Paper AV and Morris GJ (2020) Gestational diabetes mellitus testing in the COVID-19 pandemic: The problems with simplifying the diagnostic process, The Australian & New Zealand journal of obstetrics & gynaecology 60(5):671-674.
Zhu S, Meehan T, Veerasingham M and Sivanesan K (2021) COVID-19 pandemic gestational diabetes screening guidelines: A retrospective study in Australian women, Diabetes and Metabolic Syndrome, 15(1):391-395, doi:10.1016/j.dsx.2021.01.021
We'd love to know any feedback that you have about the AIHW website, its contents or reports.
The browser you are using to browse this website is outdated and some features may not display properly or be accessible to you. Please use a more recent browser for the best user experience.